Late Relapses following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era
Conclusions Patients with relapsed or refractory DLBCL experiencing relapse >1 year post-ASCT had good outcomes. Despite the relative rarity in incidence, there remains a significant risk of relapse of DLBCL post-ASCT, suggesting the need for continued monitoring for the possibility of later progression.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Immunotherapy | Leukemia | Lymphoma | Myeloma | Rituxan | Stem Cell Therapy | Stem Cells | Transplants